Abaloparatide
Abaloparatide (Tymlos)
Abaloparatide (brand name Tymlos) is a synthetic 34-amino acid peptide analog of parathyroid hormone-related protein (PTHrP) approved by the FDA in 2017 for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It is also approved for increasing bone density in men with osteoporosis. Unlike bisphosphonates, it works anabolically to stimulate new bone formation rather than simply inhibiting bone resorption.
Mechanism of Action
Abaloparatide selectively binds to the RG conformation of the PTH1 receptor (PTH1R) with high affinity, preferentially activating the cAMP/PKA signaling pathway over the beta-arrestin pathway, which results in a more transient receptor activation compared to teriparatide. This selective receptor conformation binding drives osteoblast differentiation and activity, promoting net new bone formation at both trabecular and cortical sites, leading to significant increases in bone mineral density and reductions in vertebral and non-vertebral fracture risk.
Evidence by Health Goal(12 goals)
Dosing Protocols
Subcutaneous injection into the periumbilical abdomen, at approximately the same time each day
Cycle: Maximum 18-24 months cumulative lifetime use; typically followed by antiresorptive therapy (e.g., bisphosphonate or denosumab) to consolidate gains
Administer using the pre-filled, multi-dose pen device. Patient should sit or lie down for the first few doses due to orthostatic hypotension risk. Rotate injection sites within the periumbilical abdominal region. Refrigerate pen; allow to reach room temperature before use. Total lifetime use is limited due to osteosarcoma risk signals seen in animal studies.
Safety & Side Effects
Abaloparatide carries an FDA black box warning regarding osteosarcoma risk based on dose-dependent tumor formation in rats, though no causal link has been confirmed in humans to date; cumulative lifetime use should not exceed 18-24 months. It is a Schedule-controlled prescription medication requiring physician supervision, baseline DXA scanning, and periodic monitoring of calcium levels and renal function.
Possible Side Effects
- !Injection site reactions (erythema, pain, edema) - most common, occurring in ~58% of patients
- !Dizziness and orthostatic hypotension, particularly within 4 hours of injection
- !Nausea - reported in approximately 8% of patients
- !Headache
- !Palpitations and tachycardia
- !Hypercalciuria and hypercalcemia - monitor serum and urine calcium
- !Fatigue and asthenia
- !Potential osteosarcoma risk with prolonged use (black box warning based on rat studies; human risk not established)
Interactions
- -Concomitant use with active vitamin D analogs (e.g., calcitriol) may increase risk of hypercalcemia - monitor serum calcium closely
- -Can transiently lower blood pressure - use caution with antihypertensive agents due to additive orthostatic hypotension risk
- -Diuretics (particularly loop and thiazide diuretics) may exacerbate hypercalciuria and electrolyte imbalances
- -Concurrent use with antiresorptive agents (bisphosphonates, denosumab) is not recommended during active treatment, though sequential therapy is standard of care post-course
- -Digitalis glycosides (digoxin) - hypercalcemia induced by abaloparatide may potentiate digoxin toxicity
Cost & Where to Buy
Abaloparatide (Tymlos) is a branded prescription medication with no currently available generic; retail cost is approximately $1,800-$2,800/month without insurance. Many patients pay significantly less through insurance, Medicare Part D, or manufacturer copay assistance programs (Radius Health offers a savings card). Research-peptide gray-market versions exist but are unregulated and not recommended for clinical use.
Search on Amazon